Trust Company of Vermont’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Trust Company of Vermont’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$51.7K	Hold	609	–	–	﹤0.01%	558
2025 Q3	$44.2K	Hold	609	–	–	﹤0.01%	583
2025 Q2	$39.9K	Hold	609	–	–	﹤0.01%	576
2025 Q1	$43K	Hold	609	–	–	﹤0.01%	543
2024 Q4	$40K	Hold	609	–	–	﹤0.01%	562
2024 Q3	$43K	Hold	609	–	–	﹤0.01%	540
2024 Q2	$40.4K	Hold	609	–	–	﹤0.01%	522
2024 Q1	$41.3K	Hold	609	–	–	﹤0.01%	513
2023 Q4	$37.6K	Sell	609 -1,200	-66%	-$70.5K	﹤0.01%	468
2023 Q3	$107K	Buy	+1,809	New	+$111K	0.01%	356

Other funds holding IHE

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

FIA

Foundations Investment Advisors Phoenix, Arizona $8.07B AUM 24.97% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

ACM

Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Trust Company of Vermont's IHE Position: Q4 2025 in Review

Trust Company of Vermont held its iShares US Pharmaceuticals ETF (IHE) position steady in Q4 2025 at 609 shares worth $51.7K. The position accounts for ﹤0.01% of the portfolio, ranked #558.

Trust Company of Vermont first reported a position in IHE in Q3 2023 and has held it in 10 quarters since. The position peaked at $107K in Q3 2023. 178 funds tracked by Wall St. Rank hold IHE as of Q4 2025.

Trust Company of Vermont held 609 shares of iShares US Pharmaceuticals ETF worth $51.7K as of Q4 2025.
Trust Company of Vermont left its iShares US Pharmaceuticals ETF share count unchanged in Q4 2025.
iShares US Pharmaceuticals ETF made up ﹤0.01% of Trust Company of Vermont's portfolio in Q4 2025, its #558 holding.
Trust Company of Vermont first reported a position in iShares US Pharmaceuticals ETF in Q3 2023 and has held it in 10 quarters since.
Trust Company of Vermont's iShares US Pharmaceuticals ETF position peaked at $107K in Q3 2023.
178 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q4 2025.

Based on Trust Company of Vermont's 13F filing for Q4 2025, filed 16 Jan 2026.